Sweden · Delayed Price · Currency is SEK EQL Pharma AB Statistics
Total Valuation
EQL Pharma AB has a market cap or net worth of SEK 608.31 million. The enterprise value is 980.89 million.
| Market Cap | 608.31M |
| Enterprise Value | 980.89M |
Important Dates
The next confirmed earnings date is Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EQL Pharma AB has 29.53 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 29.53M |
| Shares Outstanding | 29.53M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 2.29% |
| Owned by Institutions (%) | 1.19% |
| Float | 21.75M |
Valuation Ratios
The trailing PE ratio is 49.05 and the forward PE ratio is 25.35.
| PE Ratio | 49.05 |
| Forward PE | 25.35 |
| PS Ratio | 1.41 |
| PB Ratio | 2.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 26.54 |
| P/OCF Ratio | 21.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.15, with an EV/FCF ratio of 42.80.
| EV / Earnings | 78.23 |
| EV / Sales | 2.27 |
| EV / EBITDA | 20.15 |
| EV / EBIT | 20.15 |
| EV / FCF | 42.80 |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 1.72.
| Current Ratio | 1.92 |
| Quick Ratio | 0.95 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | 9.43 |
| Debt / FCF | 20.04 |
| Interest Coverage | 1.84 |
Financial Efficiency
Return on equity (ROE) is 5.14% and return on invested capital (ROIC) is 5.31%.
| Return on Equity (ROE) | 5.14% |
| Return on Assets (ROA) | 3.60% |
| Return on Invested Capital (ROIC) | 5.31% |
| Return on Capital Employed (ROCE) | 7.60% |
| Weighted Average Cost of Capital (WACC) | 4.91% |
| Revenue Per Employee | 7.21M |
| Profits Per Employee | 208,967 |
| Employee Count | 60 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.42 |
Taxes
In the past 12 months, EQL Pharma AB has paid 5.67 million in taxes.
| Income Tax | 5.67M |
| Effective Tax Rate | 31.13% |
Stock Price Statistics
The stock price has decreased by -77.41% in the last 52 weeks. The beta is 0.25, so EQL Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -77.41% |
| 50-Day Moving Average | 23.98 |
| 200-Day Moving Average | 47.21 |
| Relative Strength Index (RSI) | 28.31 |
| Average Volume (20 Days) | 29,237 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EQL Pharma AB had revenue of SEK 432.66 million and earned 12.54 million in profits. Earnings per share was 0.42.
| Revenue | 432.66M |
| Gross Profit | 162.84M |
| Operating Income | 47.78M |
| Pretax Income | 18.21M |
| Net Income | 12.54M |
| EBITDA | 48.69M |
| EBIT | 48.69M |
| Earnings Per Share (EPS) | 0.42 |
Balance Sheet
The company has 86.76 million in cash and 459.34 million in debt, with a net cash position of -372.58 million or -12.62 per share.
| Cash & Cash Equivalents | 86.76M |
| Total Debt | 459.34M |
| Net Cash | -372.58M |
| Net Cash Per Share | -12.62 |
| Equity (Book Value) | 267.06M |
| Book Value Per Share | 9.04 |
| Working Capital | 193.64M |
Cash Flow
In the last 12 months, operating cash flow was 28.36 million and capital expenditures -5.44 million, giving a free cash flow of 22.92 million.
| Operating Cash Flow | 28.36M |
| Capital Expenditures | -5.44M |
| Depreciation & Amortization | 21.27M |
| Net Borrowing | 9.76M |
| Free Cash Flow | 22.92M |
| FCF Per Share | 0.78 |
Margins
Gross margin is 37.64%, with operating and profit margins of 11.04% and 2.90%.
| Gross Margin | 37.64% |
| Operating Margin | 11.04% |
| Pretax Margin | 4.21% |
| Profit Margin | 2.90% |
| EBITDA Margin | 11.25% |
| EBIT Margin | 11.25% |
| FCF Margin | 5.30% |
Dividends & Yields
EQL Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | 2.06% |
| FCF Yield | 3.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EQL Pharma AB has an Altman Z-Score of 3.35 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 5 |